These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14272331)

  • 21. The synthesis of type III pneumococcal capsular polysaccharide from uridine nucleotides by a cell-free extract of Diplococcus pneumoniae type III.
    SMITH EE; MILLS GT; BERNHEIMER HP; AUSTRIAN R
    J Biol Chem; 1960 Jul; 235():1876-80. PubMed ID: 13831948
    [No Abstract]   [Full Text] [Related]  

  • 22. Type-specificity of immunological paralysis induced in mice with pneumococcal type II polysaccharide.
    MORGAN P; WATSON DW; CROMARTIE WJ
    J Bacteriol; 1953 Feb; 65(2):224-5. PubMed ID: 13034725
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunodeficiency associated with recurrent infections and an isolated in vivo inability to respond to bacterial polysaccharides: follow-up immunization with pneumococcal polysaccharides.
    Gigliotti F
    Pediatr Infect Dis J; 1988 Aug; 7(8):604. PubMed ID: 3174304
    [No Abstract]   [Full Text] [Related]  

  • 25. Age- and serotype-dependent antibody response to pneumococcal polysaccharides.
    Bossuyt X; Borgers H; Moens L; Verbinnen B; Meyts I
    J Allergy Clin Immunol; 2011 Apr; 127(4):1079-80; author reply 1080-1. PubMed ID: 21306761
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).
    Alexander J; del Guercio MF; Frame B; Maewal A; Sette A; Nahm MH; Newman MJ
    Vaccine; 2004 Jun; 22(19):2362-7. PubMed ID: 15193395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CROSS-REACTIONS OF GLUCOSE-CONTAINING POLYSACCHARIDES IN ANTIPNEUMOCOCCAL SERA. VII. THE PRECIPITATION OF TYPE IX ANTISERA BY ISOLICHENIN, AND OTHER REACTIONS.
    HEIDELBERGER M
    J Immunol; 1963 Dec; 91():735-9. PubMed ID: 14106295
    [No Abstract]   [Full Text] [Related]  

  • 28. Pneumococcal antibodies in patients with chronic obstructive pulmonary disease and their response to pneumococcal capsular polysaccharides: preliminary results.
    Davis AL; Aranda C; Christianson L; Schiffman G
    Rev Infect Dis; 1981; 3 Suppl():S183. PubMed ID: 7280447
    [No Abstract]   [Full Text] [Related]  

  • 29. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.
    Anttila M; Eskola J; Ahman H; Käyhty H
    J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ON PREPARATION OF ANTISERA FOR DETERMINATION OF C-REACTIVE PROTEIN].
    DANILOVA TA; AKOPIANTS SS
    Lab Delo; 1964; 10():280-3. PubMed ID: 14138479
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of a commercial rapid urinary antigen test to detect Streptococcus pneumoniae in patients who received 23-valent pneumococcal polysaccharide vaccine.
    Vázquez EG; Marcos MA; Vilella A; Yagüe J; Bayas JM; Mensa J
    Eur J Clin Microbiol Infect Dis; 2004 Dec; 23(12):927-9. PubMed ID: 15599657
    [No Abstract]   [Full Text] [Related]  

  • 32. ALTERED REACTIVITY OF SKIN HOMOGRAFTS IN SEVERE THERMAL INJURY.
    RAPAPORT FT; CONVERSE JM; HORN L; BALLANTYNE DL; MULHOLLAND JH
    Ann Surg; 1964 Mar; 159(3):390-5. PubMed ID: 14129385
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.
    Austrian R
    J Infect Dis; 1977 Aug; 136 Suppl():S38-42. PubMed ID: 19543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Structural organization of the pneumococcal bacterial cell].
    Padiukov LN
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):96-9. PubMed ID: 3887823
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular sizing of individual polysaccharides in polyvalent pneumococcal and meningococcal vaccines by column chromatography and immunoelectrophoresis.
    Scheers R; Dobbelaer R
    J Biol Stand; 1984 Jul; 12(3):241-6. PubMed ID: 6480610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal vaccines in adults: assessing the evolving evidence.
    Grabenstein JD; Manoff SB
    Vaccine; 2011 Aug; 29(37):6149-54. PubMed ID: 21763386
    [No Abstract]   [Full Text] [Related]  

  • 37. Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro.
    Rijkers GT; Mosier DE
    J Immunol; 1985 Jul; 135(1):1-4. PubMed ID: 3889152
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
    Prymula R; Peeters P; Chrobok V; Kriz P; Novakova E; Kaliskova E; Kohl I; Lommel P; Poolman J; Prieels JP; Schuerman L
    Lancet; 2006 Mar; 367(9512):740-8. PubMed ID: 16517274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DECREASED SUSCEPTIBILITY TO IMMUNOLOGICAL PARALYSIS WITH INCREASED AGE.
    BROOKE MS
    Transplantation; 1965 Jul; 3():478-83. PubMed ID: 14339504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.